Effect of Mirabegron in Men With Overactive Bladder and Erectile Dysfunction: A Prospective Observational Study

Area of Science:

• Urology
• Pharmacology

Background:

• Erectile dysfunction (ED) and overactive bladder (OAB) significantly impact male quality of life.
• Mirabegron, a beta-3 adrenergic agonist, is primarily used for OAB treatment.

Purpose of the Study:

• To evaluate the efficacy of mirabegron in managing symptoms of both ED and OAB in men.
• To assess the impact of mirabegron on International Index of Erectile Dysfunction-5 (IIEF-5) and Overactive Bladder Questionnaire (OAB-q) scores.

Main Methods:

• A prospective, observational study involving 250 male patients with mild to moderate ED and OAB symptoms.
• Patients were assessed using IIEF-5 and OAB-q scores at baseline and at 2, 4, 8, and 12 weeks.
• Mirabegron's impact on ED and OAB symptoms was evaluated over the study duration.

Main Results:

• Significant improvements in IIEF-5 scores were observed, with 86.25% and 91.25% of patients showing improvement at 4 and 8 weeks, respectively.
• OAB-q scores decreased from a baseline of 17.4 ± 5.5 to 13.1 ± 4.3 at 4 weeks and 12.8 ± 4.2 at 8 weeks.
• Mirabegron was well-tolerated, with no reported adverse events significantly hindering study progress.

Conclusions:

• Mirabegron demonstrates a beneficial effect on controlling OAB symptoms in men with mild to moderate ED.
• The therapeutic effects on OAB symptoms were most pronounced up to eight weeks and subsequently declined.
• Mirabegron exhibited a favorable safety profile and good tolerability in the studied patient population.